Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2011 (2011), Article ID 256460, 6 pages
Review Article

Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis

1Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB 641, Boston, MA 02115, USA
2Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
3EpiVax Inc., University of Rhode Island, Providence, RI 02903, USA

Received 19 April 2011; Accepted 14 July 2011

Academic Editor: Changiz Geula

Copyright © 2011 Wassim Elyaman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+ regulatory T (Treg) cells, defined by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis (MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with emphasis on the potential applications of Tregitope for the treatment of MS.